Immune Pharmaceuticals has entered into an exclusive license with Atlante Biotech SAS, for the patents and know-how for a new format of bispecific antibodies.   Recent data on the platform prototype bispecific antibody was shown to retain effector functions and mediate redirect killing of target cells by cytokine induced killer T cells. The bispecific antibody demonstrated direct anti-cancer effects in vitro, as well as in vivo anti-tumor activity and improved survival in a mouse xenograft mod...